Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients

IF 2 Q3 RESPIRATORY SYSTEM
F. Stehling, R. Büscher, J. Große-Onnebrink, P. Hoyer, U. Mellies
{"title":"Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients","authors":"F. Stehling, R. Büscher, J. Große-Onnebrink, P. Hoyer, U. Mellies","doi":"10.1155/2017/2602653","DOIUrl":null,"url":null,"abstract":"Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme.","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2017-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/2602653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 5

Abstract

Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme.
囊性纤维化患者重复每日一次妥布霉素疗程后的肾小球和小管肾功能
介绍。针对囊性纤维化(CF)患者铜绿假单胞菌肺部感染的抗生素治疗方案通常包括氨基糖苷类抗生素,反复疗程后可能导致慢性肾衰竭。氨基酸尿症是急性氨基糖苷性肾小管功能障碍的早期标志。我们假设尿氨基酸重吸收在重复每日一次妥布霉素治疗后减少。方法。在这项前瞻性横断面研究中,肌酐清除率由Schwartz和Cockcroft-Gault公式估计。采用离子交换色谱法测定46例CF患者的管状氨基酸重吸收,这些CF患者在每日一次给药方案中接受了多个妥布霉素疗程(6.3±10.1(1-57)),10例患者没有接受。结果。使用Cockcroft-Gault方法估计的肌酐清除率在接受妥布霉素治疗的患者中有17/46(37%)轻度降低,在未接受妥布霉素治疗的患者中有5/10(50%)轻度降低,但使用Schwartz方法的患者中没有。与终生妥布霉素疗程无关联。管状氨基酸重吸收不受每日一次妥布霉素疗程量的影响。结论。临床上,少数CF患者的eCCL没有显著减少。然而,慢性小管功能障碍不存在于CF患者反复使用妥布霉素每日一次给药方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pulmonary Medicine
Pulmonary Medicine RESPIRATORY SYSTEM-
CiteScore
10.20
自引率
0.00%
发文量
4
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信